KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Consolidated Net Income (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Consolidated Net Income for 16 consecutive years, with $102000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Consolidated Net Income rose 342.86% year-over-year to $102000.0, compared with a TTM value of $229000.0 through Sep 2025, down 64.82%, and an annual FY2024 reading of $131000.0, up 105.08% over the prior year.
  • Consolidated Net Income was $102000.0 for Q3 2025 at TherapeuticsMD, up from $6000.0 in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $127.2 million in Q2 2022 and bottomed at -$47.4 million in Q3 2021.
  • Average Consolidated Net Income over 5 years is -$3.5 million, with a median of -$41000.0 recorded in 2024.
  • The sharpest move saw Consolidated Net Income skyrocketed 398.12% in 2022, then crashed 122.67% in 2025.
  • Year by year, Consolidated Net Income stood at -$43.0 million in 2021, then soared by 168.08% to $29.2 million in 2022, then crashed by 97.75% to $658000.0 in 2023, then tumbled by 79.03% to $138000.0 in 2024, then fell by 26.09% to $102000.0 in 2025.
  • Business Quant data shows Consolidated Net Income for TXMD at $102000.0 in Q3 2025, $6000.0 in Q2 2025, and -$17000.0 in Q1 2025.